In connection with the merger between MYnd Analytics, Inc. (a Delaware corporation) and Emmaus Life Sciences, Inc., MYnd Analytics contributed its business, assets and liabilities to Telymynd, Inc., which was spun off by means of a pro rata dividend of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019. The new shares are expected to begin trading as a standalone company, at which time further updates will be provided.
Telemynd, Inc., (“Telemynd”) will now have two wholly owned subsidiaries (i) Arcadian Telepsychiatry Services LLC (“Arcadian”) which is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues and (ii) MYnd Analytics, Inc.(a California corporation) (“MYnd”), a provider of the MYnd Psychiatric EEG Evaluation Registry (PEER), a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient’s unique brain markers, reducing treatment time and treatment costs. Telemynd will be offering Arcadian’s suite of complementary telemedicine services that can be combined with MYnd ‘s PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Telemynd’s customers include major health plans, health systems, and community-based organizations.
For filings regarding the Company, please visit: sec.gov
Recent Press Releases
Documents and Other Information:
For additional information please contact:
Crescendo Communications, LLC